Ivor Geft
Los Angeles, CANPI 1043271620
Payments from drug & device makers
Across 191 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$781
- Novartis$197
- AbbVie$193
- Sanofi-aventis U.S. LLC$176
- Johnson & Johnson$171
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,912100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 61 | $1,062 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 47 | $781 |
| Novartis | 9 | $197 |
| AbbVie | 7 | $193 |
| Sanofi-aventis U.S. LLC | 4 | $176 |
| Johnson & Johnson(2 entities) | 8 | $171 |
| Daiichi Sankyo Inc. | 7 | $162 |
| Merck | 4 | $159 |
| E.r. Squibb & Sons, L.L.C. | 9 | $157 |
| Boston Scientific | 3 | $123 |
| Nestle Healthcare Nutrition Inc. | 4 | $109 |
| Baxter Healthcare | 3 | $90 |
| Pfizer | 3 | $70 |
| Alfasigma USA, Inc. | 1 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| QOL Medical, LLC | 2 | $43 |
| Ironwood Pharmaceuticals, Inc | 2 | $40 |
| Ardelyx, Inc. | 2 | $35 |
| AstraZeneca | 2 | $33 |
| Redhill Biopharma Inc. | 1 | $24 |
| Abbott | 1 | $21 |
| Sanofi | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Gilead | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $21,735 |
| XareltoRivaroxaban | 21 | $18,513 |
| EntrestoSacubitril/Valsartan | 12 | $11,495 |
| Repatha PushtronexEvolocumab | 11 | $7,721 |
| Repatha SureclickEvolocumab | 11 | $5,781 |
| Rosuvastatin Calcium | 71 | $1,084 |
| Ezetimibe | 25 | $484 |
| Amiodarone Hcl | 17 | $323 |
| Amlodipine Besylate | 45 | $262 |
| Metoprolol Tartrate | 11 | $185 |
| Metoprolol Succinate | 11 | $185 |
| Losartan Potassium | 15 | $170 |
| Levothyroxine Sodium | 12 | $155 |
| Hydralazine Hcl | 18 | $139 |
| Atorvastatin Calcium | 16 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $70 | $21,73528 claims |
| Johnson & JohnsonXarelto | $171 | $18,51321 claims |
| NovartisEntresto | $197 | $11,49512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.